Global Lonotropic Glutamate Receptor Antagonist Market Growth 2025-2031
Description
The global Lonotropic Glutamate Receptor Antagonist market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
Ionic glutamate receptor antagonists, including: the N-methyl-D-aspartate receptor, the maricin receptor, and the alpha-amino-3-hydroxy-5 methyl-4 isoxazole receptor, which are coupled to ion channels to form receptor channel complexes that mediate fast signalling.
United States market for Lonotropic Glutamate Receptor Antagonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Lonotropic Glutamate Receptor Antagonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Lonotropic Glutamate Receptor Antagonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Lonotropic Glutamate Receptor Antagonist players cover Artemis Neuroscience, VistaGen Therapeutics, Rottapharm Madaus, Amorsa Therapeutics, Newron Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Lonotropic Glutamate Receptor Antagonist Industry Forecast” looks at past sales and reviews total world Lonotropic Glutamate Receptor Antagonist sales in 2024, providing a comprehensive analysis by region and market sector of projected Lonotropic Glutamate Receptor Antagonist sales for 2025 through 2031. With Lonotropic Glutamate Receptor Antagonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Lonotropic Glutamate Receptor Antagonist industry.
This Insight Report provides a comprehensive analysis of the global Lonotropic Glutamate Receptor Antagonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Lonotropic Glutamate Receptor Antagonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Lonotropic Glutamate Receptor Antagonist market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Lonotropic Glutamate Receptor Antagonist and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Lonotropic Glutamate Receptor Antagonist.
This report presents a comprehensive overview, market shares, and growth opportunities of Lonotropic Glutamate Receptor Antagonist market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
N-Methyl-D-Aspartate Receptors
Marine Human Alginate Receptors
α-Amino-3 Hydroxy-5 Methyl-4 Isoxazole Receptors
Segmentation by Application:
Hospitals
Clinics
Research Institutes
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Artemis Neuroscience
VistaGen Therapeutics
Rottapharm Madaus
Amorsa Therapeutics
Newron Pharmaceuticals
Purdue Biopharma
Relmada Therapeutics
BioCrea GmbH
Cerecor Inc.
NeurOp Inc.
UCB SA
Novartis AG
Luc Therapeutics Inc.
Evotec AG
Key Questions Addressed in this Report
What is the 10-year outlook for the global Lonotropic Glutamate Receptor Antagonist market?
What factors are driving Lonotropic Glutamate Receptor Antagonist market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Lonotropic Glutamate Receptor Antagonist market opportunities vary by end market size?
How does Lonotropic Glutamate Receptor Antagonist break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Ionic glutamate receptor antagonists, including: the N-methyl-D-aspartate receptor, the maricin receptor, and the alpha-amino-3-hydroxy-5 methyl-4 isoxazole receptor, which are coupled to ion channels to form receptor channel complexes that mediate fast signalling.
United States market for Lonotropic Glutamate Receptor Antagonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Lonotropic Glutamate Receptor Antagonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Lonotropic Glutamate Receptor Antagonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Lonotropic Glutamate Receptor Antagonist players cover Artemis Neuroscience, VistaGen Therapeutics, Rottapharm Madaus, Amorsa Therapeutics, Newron Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Lonotropic Glutamate Receptor Antagonist Industry Forecast” looks at past sales and reviews total world Lonotropic Glutamate Receptor Antagonist sales in 2024, providing a comprehensive analysis by region and market sector of projected Lonotropic Glutamate Receptor Antagonist sales for 2025 through 2031. With Lonotropic Glutamate Receptor Antagonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Lonotropic Glutamate Receptor Antagonist industry.
This Insight Report provides a comprehensive analysis of the global Lonotropic Glutamate Receptor Antagonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Lonotropic Glutamate Receptor Antagonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Lonotropic Glutamate Receptor Antagonist market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Lonotropic Glutamate Receptor Antagonist and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Lonotropic Glutamate Receptor Antagonist.
This report presents a comprehensive overview, market shares, and growth opportunities of Lonotropic Glutamate Receptor Antagonist market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
N-Methyl-D-Aspartate Receptors
Marine Human Alginate Receptors
α-Amino-3 Hydroxy-5 Methyl-4 Isoxazole Receptors
Segmentation by Application:
Hospitals
Clinics
Research Institutes
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Artemis Neuroscience
VistaGen Therapeutics
Rottapharm Madaus
Amorsa Therapeutics
Newron Pharmaceuticals
Purdue Biopharma
Relmada Therapeutics
BioCrea GmbH
Cerecor Inc.
NeurOp Inc.
UCB SA
Novartis AG
Luc Therapeutics Inc.
Evotec AG
Key Questions Addressed in this Report
What is the 10-year outlook for the global Lonotropic Glutamate Receptor Antagonist market?
What factors are driving Lonotropic Glutamate Receptor Antagonist market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Lonotropic Glutamate Receptor Antagonist market opportunities vary by end market size?
How does Lonotropic Glutamate Receptor Antagonist break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
120 Pages
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Lonotropic Glutamate Receptor Antagonist by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Lonotropic Glutamate Receptor Antagonist by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
